Inhibikase Therapeutics, Inc. (IKT)
NASDAQ: IKT · Real-Time Price · USD
1.675
-0.025 (-1.47%)
At close: Jun 3, 2026, 4:00 PM EDT
1.670
-0.005 (-0.30%)
After-hours: Jun 3, 2026, 4:01 PM EDT
Inhibikase Therapeutics Employees
Inhibikase Therapeutics had 35 employees as of December 31, 2025. The number of employees increased by 19 or 118.75% compared to the previous year.
Employees
35
Change (1Y)
19
Growth (1Y)
118.75%
Revenue / Employee
n/a
Profits / Employee
-$1,456,037
Market Cap
287.16M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2025 | 35 | 19 | 118.75% | 35 | 0 |
| Dec 31, 2024 | 16 | 7 | 77.78% | 15 | 1 |
| Dec 31, 2023 | 9 | 2 | 28.57% | 8 | 1 |
| Dec 31, 2022 | 7 | 0 | - | 6 | 1 |
| Dec 31, 2021 | 7 | 4 | 133.33% | 6 | 1 |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Sep 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Jun 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Bicycle Therapeutics | 288 |
| Humacyte | 184 |
| Fate Therapeutics | 161 |
| Niagen Bioscience | 117 |
| Zentalis Pharmaceuticals | 106 |
| Silence Therapeutics | 88 |
| Lineage Cell Therapeutics | 77 |
| Armata Pharmaceuticals | 61 |
IKT News
- 22 days ago - Inhibikase Therapeutics Announces First Quarter 2026 Financial Results and Highlights Recent Activity - GlobeNewsWire
- 22 days ago - Inhibikase Therapeutics Earnings release: Q1 2026 - Filings
- 22 days ago - Inhibikase Therapeutics Quarterly report: Q1 2026 - Filings
- 4 weeks ago - Inhibikase Therapeutics Proxy statement: Proxy filing - Filings
- 4 weeks ago - Inhibikase Therapeutics Proxy statement: Proxy filing - Filings
- 6 weeks ago - Inhibikase Therapeutics Proxy statement: Proxy filing - Filings
- 2 months ago - Inhibikase Therapeutics enrolls first patient in IMPROVE-PAH study - TheFly
- 2 months ago - Inhibikase Therapeutics Announces Enrollment of First Patient in IMPROVE-PAH Global Phase 3 Study of IKT-001 in the Treatment of Pulmonary Arterial Hypertension - GlobeNewsWire